Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer
Gaia Griguolo(University of North Carolina at Chapel Hill), Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Giancarlo Bisagni, Guido Ficarra(University of Modena and Reggio Emilia), Antonio Frassoldati(University of Ferrara), Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Luigi Cavanna(University of Pavia), Enrico Tagliafico(University of Modena and Reggio Emilia), Maria Vittoria Dieci(Istituto Oncologico Veneto), Federico Piacentini(Azienda Unita' Sanitaria Locale Di Modena), Federica Miglietta(University of Padua), Aleix Prat(Hospital Clínic de Barcelona), Daniele Generali(University of Trieste)
Cited by 25
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k